Tirzepatide and sleeve gastrectomy compared to semaglutide for 1-year weight loss and glycemic control in type 2 diabetes
Background
Type 2 diabetes (T2D) and obesity are highly prevalent and interconnected conditions, posing significant global health challenges. While treatment options have expanded, including novel GLP-1/GIP receptor agonists and bariatric surgery, direct real-world comparisons of their long-term efficacy and safety remain limited. Understanding the comparative effectiveness of these modern interventions, particularly semaglutide, tirzepatide, and sleeve gastrectomy, is crucial for optimizing clinical practice and guiding patient-centered care strategies in this complex patient population.
Study Design
This retrospective cohort study utilized the Epic Cosmos de-identified electronic health record dataset, encompassing data from 1633 hospitals and 37,900 clinics across 280 health systems in the USA. Researchers included adults with BMI of at least 35 kg/m2 and HbA1c above 6.4% who initiated at least 12 months of therapy with semaglutide or tirzepatide (attaining maintenance doses), or who underwent sleeve gastrectomy. The primary outcome was a composite of achieving at least 20% bodyweight loss and HbA1c below 5.7% at 1 year post-index. Multivariable logistic regression adjusted for various confounders, including age, sex, race, baseline BMI, and comorbidity indices. Safety outcomes, such as emergency department visits and new prescriptions for gastro-oesophageal reflux disease or nausea, were also prespecified and descriptively analyzed.
Results
The study analyzed a substantial cohort, with a total of 468,712 patients included in the final analysis. However, the provided abstract concludes before detailing the specific findings regarding the primary composite outcome (attainment of at least 20% bodyweight loss and HbA1c below 5.7%) or the prespecified safety outcomes (emergency department visits, new gastro-oesophageal reflux disease or nausea prescriptions). The abstract does not present any quantitative results, p-values, or comparative efficacy data for semaglutide, tirzepatide, or sleeve gastrectomy regarding weight loss, glycemic control, or safety profiles. Therefore, specific numerical findings from this large real-world comparison are not available in the provided text.
Key Findings
- Specific quantitative findings regarding weight loss, glycemic control, and safety outcomes were not provided in the abstract.
Why It Matters
While specific results are not detailed in the abstract, this study's design to directly compare semaglutide, tirzepatide, and sleeve gastrectomy in a large real-world cohort of type 2 diabetes and obesity patients is highly significant. Such real-world comparative effectiveness data is critical for clinicians and patients to make informed treatment decisions, especially as these interventions become more widely adopted. Understanding which treatment offers the best balance of weight loss, glycemic control, and safety in routine clinical practice could refine existing treatment algorithms. If the full findings demonstrate clear superiority of one intervention, it could influence prescribing patterns and patient counseling, potentially leading to more personalized and effective management strategies for individuals struggling with both conditions.
semaglutide
tirzepatide
sleeve gastrectomy
obesity
type 2 diabetes
weight loss